Notice of Annual General Meeting.

5 June 2025

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Notice of Annual General Meeting

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, announces that notice of the Annual General Meeting of the Company has today been posted to shareholders and will be available shortly on the Company's website (the "AGM").

The Company's AGM will be held at 10.00 a.m. on 30 June 2025 at the offices of Simmons & Simmons LLP, CityPoint, 1 Ropemaker Street, London, EC2Y 9SS.

The Company announced on 12 May 2025 that it had expected to release its audited results for the year ended 31 December 2024 on 19 June 2025. Due to the ongoing workstreams associated with the completion of the divestment of the CDMO operations and non-core products, it is now anticipated that the Company will publish the audited results and send the annual report and accounts to shareholders  (the "2024 Annual Report and Accounts") in late June 2025.  

As the AGM is required to be held on 30 June 2025 at the latest and the 2024 Annual Report and Accounts will not be available to be circulated in sufficient time for the AGM, the AGM business does not include a resolution to receive the 2024 Annual Report and Accounts. As a result, the Company's Directors intend to hold a separate general meeting at a later date for the shareholders to vote on a resolution to receive  the 2024 Annual Report and Accounts (the "General Meeting"). The Company will confirm the proposed date of the General Meeting as soon as practicable, however, it is currently anticipated that the date will be held in early August.

For further information, please contact:

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, the Health and Her product range supporting the hormonal lifecycle, the UltraDEX and Dentyl oral care product ranges, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples and are sold in over 90 countries worldwide. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.